Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer
patients with advanced primary hepatocellular carcinoma
The primary endpoint is best overall response rate within 20 weeks after registration